Regulus Therapeutics Inc

NASDAQ:RGLSUnited States

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.

Contact Information

Headquarters

4224 Campus Point Court, Suite 210SAN DIEGO, CA, United States 92121

Phone

858-202-6300

Fax

302-655-5049

Executives

Independent Chairman of the Board

Stelios Papadopoulos

President, Head of Research & Development, Director

Preston Klassen

Chief Executive Officer, Director

Joseph Hagan

Chief Financial Officer

Cris Calsada

Senior Vice President, General Counsel

Christopher Aker